ExpressCT value Leverage GeneCentric’s GenomicsNext platform and ctDNA‑based gene expression inference to offer dynamic tumor profiling that complements static DNA mutation tests, enabling more precise patient stratification for targeted therapies and biomarker discovery.

Clinical collaboration Target biopharma and diagnostic partners developing antibody‑drug conjugates and RNA‑based diagnostics; position GeneCentric as a collaborator for expression‑driven companion diagnostics and clinical trial enrichment using liquid biopsy solutions.

Expansion momentum Capitalize on recent funding and product launches such as ExpressCT Rewind to re‑analyze existing liquid biopsy data, offering customers a path to unlock previously generated samples and extend market reach without new sample collection.

Strategic partnerships Highlight ongoing collaborations with Tempus for PurIST and Labcorp for AF‑PRS development to reassure potential customers of validated workflows, robust data integration, and real‑world evidence supporting adoption in clinical practice.

Market positioning Position GeneCentric as a multidisciplinary precision medicine player with a focused mid‑size company profile, enabling faster decision cycles and tailored outreach to mid‑tier biopharma, academic researchers, and CROs seeking innovative blood‑based biomarkers.